Federal science minister Kim Carr outlines his thinking and his philosophy to Australian Life Scientist.

Genome-wide association studies show the way forward for global genomic research.

So, you're a small biotech looking to get into bed with Big Pharma. Kate McDonald spoke to Merck's head of research Ismail Kola about life on the dark side.

How did a chemistry PhD become one of the 50 most powerful women in business by hooking up the world's largest computer company with the life sciences? Kate McDonald spoke to IBM's Carol Kovac, who admits to being rather excited about the world of biology.

Sydney-based Narhex has begun recruiting for an early-stage trial of an HIV drug. Helen Schuller spoke with the company's MD, John Mills, about HIV drug development, working in China, and good management.

Ruth Beran asked Sir Gustav Nossal about Australia's latest institute -- which just happens to bear his name.

Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model.

Cochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers.

Kevin Davies spoke with Jonathan Rothberg, the founder of 454 Life Sciences, on the eve of the publication of his company's landmark paper in Nature.

Australian Biotechnology News editor-in-chief Iain Scott spoke with renowned industry analyst Cynthia Robbins-Roth about what it will take to keep biotech alive.

Producing products from human blood plasma is a lucrative business and the Chinese market provides a significant long-term opportunity, AVT Plasma's CEO tells Ruth Beran.

Ruth Beran discovers how one of Australia's great bioentrepreneurs has moved from inspiring shareholders to inspiring a nation.

Brian McNamee has been at the helm of Australia's oldest - and now biggest - life-sciences company, CSL, for 15 years. He guided the company through its public listing in 1994 and has overseen its growth to a market capitalisation of $6.8 billion. He spoke with Melissa Trudinger about CSL's research and development programs, and his vision for the company's future.

One of the leading lights of international stem cell research will be in Australia next week, as a de facto ambassador for Wales as well as to discuss his research.

Dr John Raff tells Graeme O'Neill why Australia's agbiotech industry is struggling.